Abstract: |
The new Ru<sup>II</sup> chloroquine complexes [Ru(η<sup>6</sup>-arene) (CQ)Cl<sub>2</sub>] (CQ = chloroquine; arene = p-cymene 1, benzene 2), [Ru(η<sup>6</sup>-p-cymene)(CQ)(H<sub>2</sub>O)<sub>2</sub>][BF <sub>4</sub>]<sub>2</sub> (3), [Ru(η<sup>6</sup>-p-cymene)(CQ)(en)][PF <sub>6</sub>]<sub>2</sub> (en = ethylenediamine) (4), and [Ru(η<sup>6</sup>- p-cymene)(η<sup>6</sup>-CQDP)][BF<sub>4</sub>]<sub>2</sub> (5, CQDP = chloroquine diphosphate) have been synthesized and characterized by use of a combination of NMR and FTIR spectroscopy with DFT calculations. Each complex is formed as a single coordination isomer: In 1-4, chloroquine binds to ruthenium in the η<sup>1</sup>-N mode through the quinoline nitrogen atom, whereas in 5 an unprecedented η<sup>6</sup> bonding through the carbocyclic ring is observed. 1, 2, 3, and 5 are active against CQ-resistant (Dd2, K1, and W2) and CQ-sensitive (FcB1, PFB, F32, and 3D7) malaria parasites (Plasmodium falciparum); importantly, the potency of these complexes against resistant parasites is consistently higher than that of the standard drug chloroquine diphosphate. 1 and 5 also inhibit the growth of colon cancer cells, independently of the p53 status and of liposarcoma tumor cell lines with the latter showing increased sensitivity, especially to 1 (IC<sub>50</sub> 8 μM); this is significant because this type of tumor does not respond to currently employed chemotherapies. © 2009 American Chemical Society. |